Table 3.

Selected studies evaluating scarring alopecia outcomes following IL-23 inhibitor use

Author	Indication	Enrollment	Study Drug Regimen	Concurrent Therapies	Outcomes
Nagshabandi et al. [32]	DC	2	Risankizumab, in-clinic injection every 3 months	Patient 1: Not reported Patient 2: Topical clindamycin 1% solution daily	At 13-month follow-up, patient 1 reported improvement of roughly 70% in scalp lesions by the fifth dose, with no new lesions or draining nodules; signs of hair growth evident At four-month follow-up, patient 2 experienced improvements in skin lesions by the third dose
Awad et al. [33]	DC	1	Tildrakizumab, two doses of subcutaneous injection given 4 weeks apart	Not reported	At eight-week follow-up, the patient increased hair density and reduced the number of pustules Patient reported alleviated scalp tenderness and hair regrowth
Trindade de Carvalho et al. [34]	FFA/LPP	1	Tildrakizumab, 100 mg subcutaneously at weeks 0, 4, and subsequently 12 weekly	Minoxidil 1–2 mg/day and dutasteride 0.5 mg/day	At 16-week follow-up, patient experienced symptomatic improvements At 13-month follow-up, remission was maintained No adverse reactions reported